Vir Biotechnology: Hepatitis Delta Data Momentum and Oncology Expansion with Astellas
With ECLIPSE studies fully enrolled and a new cash infusion, Vir is gearing up for pivotal readouts and a broader pipeline.
VIR · Earnings Call · 2026-08-05
Hepatitis Delta: On the Cusp of a Pivotal Data Wave
Vir Biotechnology's second-quarter 2026 update was dominated by hepatitis delta, where the company has now completed enrollment across all three ECLIPSE registrational studies. “We are pleased to share that we completed enrollment in ECLIPSE 2 during the second quarter.” — Marianne De Backer, Chief Executive Officer · 2026-08-05 This sets the stage for a catalyst-rich period: top-line data from ECLIPSE 1 in Q4 2026, followed by ECLIPSE 2 and 3 in Q1 2027.
The company's confidence is buoyed by compelling 96-week data from the SOLSTICE study, presented at EASL. “By week 96, 88% of patients in the intention-to-treat analysis receiving elebsiran and tobevibart achieved undetectable virus compared with 53% of patients receiving tobevibart monoclonal antibody therapy alone.” — Marianne De Backer, Chief Executive Officer · 2026-08-05 This reinforces the undetectable virus endpoint as the gold standard, a theme echoed by key opinion leaders. Indeed, one KOL described the 88% TND rate as "the best-ever target not detected rate in 50 years of HDV treatment experience."
The only good virus is a dead virus.
Beyond efficacy, Vir is focusing on regulatory readiness and patient convenience. The company is conducting human factor studies to support potential at-home administration, and pursuing co-packaging of elebsiran and tobevibart. human factor study progress, along with the completed drug substance PPQ batches, positions the program for a smooth BLA filing. The recent approval of bulevirtide in the US is seen as a tailwind, with Reflex testing potentially expanding diagnosis rates from the current ~10-15%.
Oncology: Expanding the Platform with Astellas
In oncology, the collaboration with Astellas has rapidly advanced VIR-5500, a dual-masked PSMA-targeted T-cell engager. The company has initiated three monotherapy expansion cohorts and three combination cohorts, including with darolutamide in metastatic hormone-sensitive prostate cancer. “Together with Astellas, we have launched scale-up efforts and have secured a manufacturing contract to support the VIR-5500 Phase III program.” — Marianne De Backer, Chief Executive Officer · 2026-08-05 This is a strategic pivot toward a broader combination therapy franchise.
This momentum builds on earlier commitments. In the prior quarter's call, management reiterated its ambition to initiate pivotal trials in 2027: “Our goal, pending data, is to start pivotal trials in 2027.” — Marianne De Backer, Chief Executive Officer · 2026-05-06 The expansion cohorts are designed to inform that pathway.
Meanwhile, VIR-5818 (HER2) and VIR-5525 (EGFR) continue dose escalation, with updates expected in the second half of 2026. The pipeline also includes seven preclinical assets, underscoring the scalability of the PRO-XTEN platform.
Financial Discipline and a Strengthened Balance Sheet
The Astellas deal provided a substantial cash infusion: $315 million in Q2, including a $240 million upfront payment. This lifted cash and investments to $1.01 billion, extending the runway into the second half of 2028. Net income swung to $80.1M in Q2 2026, versus a $111.0M loss a year ago, though the underlying R&D spending remains elevated.
The company's stock, however, has been moribund, trading at roughly $11, down over 80% from its 2021 peak. The recent flat tape suggests investors are waiting for the ECLIPSE readouts. With completed enrollment in ECLIPSE 2 now behind it, Vir is entering a period where data, not rhetoric, will define its trajectory.